Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 16:00:02 2024-04-26 EDT 		5-day change 1st Jan Change
44.85 USD +0.34% Intraday chart for Bristol-Myers Squibb Company -8.34% -12.59%
04-26 S&P 500 Q1 earnings estimated growth improves; stocks up for week RE
04-26 Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 150,473 140,172 138,395 159,703 104,403 90,915 - -
Enterprise Value (EV) 1 181,813 174,584 165,982 189,770 131,531 129,253 121,698 117,130
P/E ratio - -15.5 x 20 x 24.4 x 13.3 x -19.4 x 8.16 x 8.13 x
Yield 2.62% 2.97% 3.22% 3.04% 4.5% 5.36% 5.66% 5.79%
Capitalization / Revenue 5.76 x 3.3 x 2.98 x 3.46 x 2.32 x 1.98 x 1.97 x 2.05 x
EV / Revenue 6.95 x 4.11 x 3.58 x 4.11 x 2.92 x 2.81 x 2.63 x 2.65 x
EV / EBITDA 18.3 x 9.64 x 8.1 x 9.43 x 7.52 x 23.5 x 6.71 x 7.15 x
EV / FCF 25.1 x 13.1 x 10.9 x 15.9 x 10.4 x 9.1 x 8.65 x 8.97 x
FCF Yield 3.98% 7.62% 9.18% 6.3% 9.62% 11% 11.6% 11.1%
Price to Book 2.12 x 3.7 x 3.73 x 5.02 x 3.48 x 3.96 x 3.44 x 3.37 x
Nbr of stocks (in thousands) 2,344,185 2,259,752 2,219,645 2,219,645 2,034,758 2,027,100 - -
Reference price 2 64.19 62.03 62.35 71.95 51.31 44.85 44.85 44.85
Announcement Date 20-02-06 21-02-04 22-02-04 23-02-02 24-02-02 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 26,145 42,518 46,385 46,159 45,006 45,956 46,252 44,255
EBITDA 1 9,945 18,118 20,493 20,123 17,498 5,494 18,133 16,385
EBIT 1 8,199 17,426 19,830 19,442 16,785 4,043 16,873 15,829
Operating Margin 31.36% 40.98% 42.75% 42.12% 37.3% 8.8% 36.48% 35.77%
Earnings before Tax (EBT) 1 4,975 -6,871 8,098 7,713 8,440 -5,024 11,004 10,683
Net income 1 3,439 -9,015 6,994 6,327 8,025 -4,219 10,402 10,328
Net margin 13.15% -21.2% 15.08% 13.71% 17.83% -9.18% 22.49% 23.34%
EPS 2 - -3.990 3.120 2.950 3.860 -2.309 5.494 5.518
Free Cash Flow 1 7,231 13,299 15,234 11,948 12,651 14,204 14,077 13,058
FCF margin 27.66% 31.28% 32.84% 25.88% 28.11% 30.91% 30.44% 29.51%
FCF Conversion (EBITDA) 72.71% 73.4% 74.34% 59.37% 72.3% 258.54% 77.63% 79.7%
FCF Conversion (Net income) 210.26% - 217.82% 188.84% 157.64% - 135.33% 126.44%
Dividend per Share 2 1.680 1.840 2.010 2.190 2.310 2.403 2.540 2.596
Announcement Date 20-02-06 21-02-04 22-02-04 23-02-02 24-02-02 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 11,985 11,648 11,887 11,218 11,406 11,337 11,226 10,966 11,477 11,865 11,488 11,203 11,628 11,858 11,711
EBITDA 1 4,832 5,305 7,812 7,424 4,288 5,030 4,268 4,539 3,816 - 4,226 4,419 4,755 - -
EBIT 1 4,670 5,267 5,229 4,836 4,110 4,857 4,251 4,360 3,630 -8,329 4,212 4,042 4,192 4,940 4,660
Operating Margin 38.97% 45.22% 43.99% 43.11% 36.03% 42.84% 37.87% 39.76% 31.63% -70.2% 36.66% 36.08% 36.06% 41.66% 39.79%
Earnings before Tax (EBT) 1 - - 1,958 2,209 1,859 2,770 1,859 2,137 1,674 -11,516 2,643 1,606 1,964 - -
Net income 1 2,372 1,278 1,421 1,606 2,022 2,262 2,073 1,928 1,762 -11,911 1,688 1,514 2,493 - -
Net margin 19.79% 10.97% 11.95% 14.32% 17.73% 19.95% 18.47% 17.58% 15.35% -100.39% 14.7% 13.52% 21.44% - -
EPS 2 1.070 0.5900 0.6600 0.7500 0.9500 1.070 0.9900 0.9300 0.8700 -5.890 0.9094 0.8399 1.226 1.810 1.690
Dividend per Share 2 0.5400 0.5400 0.5400 0.5400 0.5700 0.5700 0.5700 0.5700 0.6000 - 0.6072 0.6122 0.6222 0.6744 0.6744
Announcement Date 22-02-04 22-04-29 22-07-27 22-10-25 23-02-02 23-04-27 23-07-27 23-10-26 24-02-02 24-04-25 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 31,340 34,412 27,587 30,067 27,128 38,338 30,783 26,214
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.151 x 1.899 x 1.346 x 1.494 x 1.55 x 6.978 x 1.698 x 1.6 x
Free Cash Flow 1 7,231 13,299 15,234 11,948 12,651 14,204 14,077 13,058
ROE (net income / shareholders' equity) 24.5% 33% 45.7% 49.4% 51.6% 4.09% 78.6% 66.1%
ROA (Net income/ Total Assets) - 11.9% 14.8% 16% 8.36% 0.45% 12% 10.9%
Assets 1 - -75,809 47,265 39,445 95,989 -937,495 86,588 94,785
Book Value Per Share 2 30.30 16.80 16.70 14.30 14.70 11.30 13.00 13.30
Cash Flow per Share 2 4.710 6.220 7.300 6.090 6.670 5.350 8.470 7.680
Capex 1 836 753 973 1,118 1,209 1,069 1,145 1,042
Capex / Sales 3.2% 1.77% 2.1% 2.42% 2.69% 2.33% 2.48% 2.35%
Announcement Date 20-02-06 21-02-04 22-02-04 23-02-02 24-02-02 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
44.85 USD
Average target price
54.02 USD
Spread / Average Target
+20.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-12.59% 90.92B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Financials Bristol-Myers Squibb Company